Article thumbnail

The Clinical Spectrum of Missense Mutations of the First Aspartic Acid of cbEGF-like Domains in Fibrillin-1 Including a Recessive Family

By Yvonne Hilhorst-Hofstee, Marry EB Rijlaarsdam, Arthur JHA Scholte, Marietta Swart-van den Berg, Michel IM Versteegh, Iris van der Schoot-van Velzen, Hans-Joachim Schäbitz, Emilia K Bijlsma, Marieke J Baars, Wilhelmina S Kerstjens-Frederikse, Jacques C Giltay, Ben C Hamel, Martijn H Breuning and Gerard Pals


Marfan syndrome (MFS) is a dominant disorder with a recognizable phenotype. In most patients with the classical phenotype mutations are found in the fibrillin-1 gene (FBN1) on chromosome 15q21. It is thought that most mutations act in a dominant negative way or through haploinsufficiency. In 9 index cases referred for MFS we detected heterozygous missense mutations in FBN1 predicted to substitute the first aspartic acid of different calcium-binding Epidermal Growth Factor-like (cbEGF) fibrillin-1 domains. A similar mutation was found in homozygous state in 3 cases in a large consanguineous family. Heterozygous carriers of this mutation had no major skeletal, cardiovascular or ophthalmological features of MFS. In the literature 14 other heterozygous missense mutations are described leading to the substitution of the first aspartic acid of a cbEGF domain and resulting in a Marfan phenotype. Our data show that the phenotypic effect of aspartic acid substitutions in the first position of a cbEGF domain can range from asymptomatic to a severe neonatal phenotype. The recessive nature with reduced expression of FBN1 in one of the families suggests a threshold model combined with a mild functional defect of this specific mutation. © 2010 Wiley-Liss, Inc

Topics: Mutation in Brief
Publisher: Wiley Subscription Services, Inc., A Wiley Company
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1994). A compound-heterozygous Marfan patient: two defective fibrillin alleles result in a lethal phenotype.
  2. (2003). Allelic variation in normal human FBN1 expression in a family with Marfan syndrome: a potential modifier of phenotype?
  3. (2006). Aneurysm syndromes caused by mutations in the TGF-beta receptor.
  4. (2007). Cellular and molecular studies of Marfan syndrome mutations identify co-operative protein folding in the cbEGF12-13 region of fibrillin-1.
  5. (2003). Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome.
  6. (2007). Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study.
  7. (2002). Evaluation and application of denaturing HPLC for mutation detection in Marfan syndrome: Identification of 20 novel mutations and two novel polymorphisms in the FBN1 gene.
  8. (2007). Extracellular control of TGFbeta signalling in vascular development and disease.
  9. (2003). Fibrillin controls TGF-beta activation. Nat Genet 33:331-332. Hilhorst-Hofstee et al.
  10. (1996). Fibrillin-1 (FBN1) mutations in patients with thoracic aortic aneurysms.
  11. (2006). Fibrillins: from biogenesis of microfibrils to signaling functions.
  12. (1993). Four novel FBN1 mutations: significance for mutant transcript level and EGF-like domain calcium binding in the pathogenesis of Marfan syndrome.
  13. (1993). Genomic organization of the sequence coding for fibrillin, the defective gene product in Marfan syndrome. Hum Mol Genet 2:1762.
  14. (2007). Homozygosity for a FBN1 missense mutation: clinical and molecular evidence for recessive Marfan syndrome.
  15. (1984). Homozygosity for autosomal dominant Marfan syndrome.
  16. (2008). Intracranial hypertension in 2 children with marfan syndrome.
  17. (1991). Key residues involved in calciumbinding motifs in EGF-like domains.
  18. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein.
  19. (1990). Location on chromosome 15 of the gene defect causing Marfan syndrome.
  20. (2003). Making sense of latent TGFbeta activation.
  21. (1991). Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene.
  22. (2000). Mouse models of genetic diseases resulting from mutations in elastic fiber proteins.
  23. (1997). Mutation screening of all 65 exons of the fibrillin-1 gene in 60 patients with Marfan syndrome: report of 12 novel mutations.
  24. (2002). Mutations of FBN1 and genotype-phenotype correlations in Marfan syndrome and related fibrillinopathies.
  25. (1999). Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1.
  26. (1977). Probable autosomal recessive Marfan syndrome.
  27. (1988). Probable homozygotic form of the Marfan syndrome in a newborn child.
  28. (1996). Revised diagnostic criteria for the Marfan syndrome.
  29. (1996). Solution structure of a pair of calciumbinding epidermal growth factor-like domains: implications for the Marfan syndrome and other genetic disorders.
  30. (1997). Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome.
  31. (2004). TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome.
  32. (2006). The molecular genetics of Marfan syndrome and related disorders.
  33. (1987). The solution structure of human epidermal growth factor.
  34. (1959). Transforming growth factor beta in cardiovascular development and function. Cytokine Growth Factor Rev 14:391-407. Mutations of First Aspartic Acid of cbEGF-like Domains
  35. (1989). Two-dimensional echocardiographic aortic root dimensions in normal children and adults.
  36. (2003). Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database.